Skip to content

Impact of Airways Function After HFNC Evaluated by IOS

Impact of Airways Function After Short-term Use of High-flow Nasal Cannula Gas Therapy Evaluated by Impulse Oscillometry Systems in Stable Chronic Obstructive Pulmonary Disease Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05130112
Enrollment
26
Registered
2021-11-22
Start date
2019-12-13
Completion date
2020-09-09
Last updated
2021-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD, Small Airway Disorders

Keywords

high-flow nasal cannula, high nasal flow, chronic obstructive pulmonary disease (COPD), airway impedance, distal airway, peripheral airway, airway resistance

Brief summary

In addition to pharmacological treatment, nonpharmacological treatment with high-flow nasal cannula (HFNC) may play a vital role in the treatment of patients with chronic obstructive pulmonary disease (COPD). The impulse oscillation system (IOS) is new noninvasive technique to measure the impedance of different portions of the airway with higher sensitivity than that of the conventional pulmonary function test (PFT). However, whether IOS is an appropriate technique to evaluate the efficacy of HFNC in improving the impedance of peripheral small airways in patients with COPD is unclear.

Detailed description

Participants with stable COPD from the chest medicine outpatient department will be randomized into two groups receiving HFNC or nasal cannula (NC) for 10 min followed by a 4-week washout period and crossover alternatively. We used a novel analytical measurement technique, IOS, to detect the difference in airway impedance in the participants after the HFNC or NC interventions. All data, namely IOS parameters, transcutaneous partial pressure of carbon dioxide, peripheral oxygen saturation, body temperature, respiratory rate, pulse rate, blood pressure, and PFT results at the time of pre-HFNC, post-HFNC, pre-NC, and post-NC, were analysed using SPSS (version 25.0, IBM, Armonk, NY, USA).

Interventions

DEVICEhigh flow nasal cannula and nasal cannula

HFNC was administered using the MyAIRVO 2 device (Fisher & Paykel Healthcare, Auckland, New Zealand), which provides humidification and high-flow medical gas through an Optiflow NC interface (Fisher & Paykel Healthcare, Auckland, New Zealand) is administered for 10 min.. NC is administered for 10 min.

Sponsors

Fu Jen Catholic University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* age of 20 to 75 years old * diagnosis of COPD made by pulmonologist (Kuo YL) if the patient had a long-term smoking or noxious gas exposure history, typical clinical manifestations, and airflow limitation with a postbronchodilator FEV1/FVC ratio of \< 0.7 in spirometry,4 and * provision of written informed consent.

Exclusion criteria

* severe and unstable comorbidities or active malignancy * history of obstructive sleep apnoea syndrome * COPD exacerbation within the 4 weeks prior * current use of long-term oxygen therapy or noninvasive ventilation or use within the 6 weeks prior * cognitive impairment or a psychiatric disorder * pregnancy

Design outcomes

Primary

MeasureTime frameDescription
R5immediately after 10 minutes of HFNC or NCChanges of R5
R5%immediately after 10 minutes of HFNC or NCChanges of R5%
R20immediately after 10 minutes of HFNC or NCChanges of R20
R20%immediately after 10 minutes of HFNC or NCChanges of R20%
Changes of R5-20immediately after 10 minutes of HFNC or NCR5-20
X5-predictedimmediately after 10 minutes of HFNC or NCChanges of X5-predicted
X5-predicted%immediately after 10 minutes of HFNC or NCChanges of X5-predicted%
Changes of Fresimmediately after 10 minutes of HFNC or NCFres
Changes of Fres%immediately after 10 minutes of HFNC or NCFres%
Changes of Aximmediately after 10 minutes of HFNC or NCAx
Ax%immediately after 10 minutes of HFNC or NCChanges of Ax%

Secondary

MeasureTime frameDescription
Changes of FEV3immediately after 10 minutes of HFNC or NCFEV3
FEV3%immediately after 10 minutes of HFNC or NCChanges of FEV3%
FEV3/FVC%immediately after 10 minutes of HFNC or NCChanges of FEV3/FVC%
TcPCO2immediately after 10 minutes of HFNC or NCChanges of TcPCO2
Changes of MMEF%immediately after 10 minutes of HFNC or NCMMEF%
PEFimmediately after 10 minutes of HFNC or NCChanges of PEF
PEF%immediately after 10 minutes of HFNC or NCChanges of PEF%
MMEFimmediately after 10 minutes of HFNC or NCChanges of MMEF
Body temperatureimmediately after 10 minutes of HFNC or NCChanges of body temperature
pulse rateimmediately after 10 minutes of HFNC or NCChanges of pulse rate
respiratory rateimmediately after 10 minutes of HFNC or NCChanges of respiratory rate
both systolic and diastolic blood pressureimmediately after 10 minutes of HFNC or NCChanges of both systolic and diastolic blood pressure
SpO2immediately after 10 minutes of HFNC or NCChanges of SpO2
FEV1immediately after 10 minutes of HFNC or NCChanges of FEV1
FEV1%immediately after 10 minutes of HFNC or NCChanges of FEV1%
FVCimmediately after 10 minutes of HFNC or NCChanges of FVC
FVC%immediately after 10 minutes of HFNC or NCChanges of FVC%
FEV1/FVC%immediately after 10 minutes of HFNC or NCChanges of FEV1/FVC%

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026